Mr. James Passin reports

BIOVAXYS LICENSEE SPAYVAC-FOR-WILDLIFE, INC., REPORTS FURTHER POSITIVE SINGLE-DOSE EFFICACY DATA FOR ITS IMMUNOCONTRACEPTIVE VACCINE AND INITIATION OF REGULATORY SUBMISSION PROCESS

The results from a collaborative research project conducted by Biovaxys Technology Corp. and SpayVac for Wildlife Inc. in the Bavarian Forest National Park in Germany have recently been published in the European Journal of Wildlife Research. A single dose of its immunocontraceptive vaccine (SpayVac) significantly reduced fertility to 11 per cent in vaccinated deer compared with a fertility rate of 86 per cent in control animals. At the core of SpayVac is a patented technology for a liposome-based delivery platform (designed to create long-lasting, targeted immune responses) that is licensed from Biovaxys. The liposomes are composed of naturally occurring phospholipids. These liposomes encapsulate the antigen and improve the immune system's response to vaccination.

The one-year study was done with 47 free-ranging red deer (Cervus elaphus) and used camera traps, GPS (Global Positioning System) collars and fecal progesterone metabolites to intensively monitor pregnancies. The contraceptive efficacy of SpayVac has now been clinically validated in three distinct deer species: fallow deer (Dama dama), white-tailed deer (Odocoileus virginianus) and red deer. These results indicate a broad potential for SpayVac to be successfully applied across a wide range of deer populations.

SpayVac for Wildlife has initiated the submission process to secure regulatory approval for SpayVac, its first product targeting feral horses and free-ranging deer populations. Kenneth Kovan, president and chief operating officer of Biovaxys, said: "SpayVac is further clinical demonstration of the single-dose, long-duration efficacy provided by our vaccine technology platform, and, with tens of millions of deer worldwide, the commercial potential for SpayVac is significant. We anticipate a healthy royalty stream from SpayVac vaccine sales."

Deer populations can double in size every two years, especially where natural predators have been extirpated. In the United States, overabundant deer can cause extensive damage to agricultural crops, and, in suburban areas, they are one of the primary hosts for ticks that carry and spread Lyme disease, contribute to animal-vehicle collisions, damage vegetation, can adversely affect other wildlife, and facilitate disease transmission of other tick-borne diseases. Managing deer populations through non-lethal means is of significant interest, especially where hunting is not possible or favoured. Surgical sterilization is available, though it involves higher costs, greater invasiveness and requires more time. Long-lasting, single-dose immunocontraception provides an alternative that is less invasive and may be more cost-effective. A single injection of SpayVac reduced fertility to 0 to 20 per cent for three to five years in fallow and white-tailed deer studies. "It's just not feasible to vaccinate free-ranging deer, give them a booster and then administer boosters on an annual basis. SpayVac is a game changer in that respect. It can have a meaningful impact in efforts to manage overabundant deer populations," said Dr. Mark Fraker, vice-president of operations at SpayVac for Wildlife.

SpayVac trials with feral horses, farmed trout, Asian elephants and other species are continuing. Tom D'Orazio, SpayVac's chief executive officer, said: "These results are another example of replication and proof of concept that SpayVac pZP vaccine is very effective. It replicates other results we've seen in deer and other species. Therefore, we continue developing indications and other vaccines for markets where SpayVac might offer an appealing alternative to spaying or short-acting immunocontraceptives in farm-production animals and companion animals."

About Biovaxys Technology Corp.

Biovaxys Technology, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix tumour cell construct platform for treating cancers, infectious disease, antigen desensitization for food allergy and other immunological diseases. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust and persistent immune response. The company's clinical-stage pipeline includes maveropepimut-S (MVP-S), based on the DPX platform, in phase IIB clinical development for advanced relapsed-refractory diffuse large B-cell lymphoma (DLBCL) and platinum-resistant ovarian cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T-cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumour immune response. Biovaxys is also developing DPX+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously; DPX-RSV for respiratory syncytial virus; DPX+rPA for peanut allergy prophylaxis; and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix neoantigen tumour cell construct platform for refractive late-stage ovarian cancer.

Biovaxys common shares are listed on the Canadian Securities Exchange under the stock symbol BIOV and trade on the Frankfurt Bourse (FRA: 5LB) and in the United States on the OTC Markets (OTCQB: BVAXF).

We seek Safe Harbor.